Shots:
The US FDA has granted FTD to MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD
MK-2060 is currently being evaluated in the P-II study to evaluate the efficacy & safety of two different doses in patients with ESRD who received hemodialysis via an arteriovenous graft (AVG). Future studies using MK-2060 will benefit from the data from this trial to help with dose selection
MK-2060 is a novel inhibitor of Factor XI & is indicated for the prevention of thrombosis in patients with ESRD. The therapy is intended to function by preventing both the downstream activity of the activated protein and the activation of Factor XI
Ref: Businesswire | Image: Merck
